| Listed site | cro | cro |
|---|
| Summary | Global preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities. | Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries. |
|---|
| Services | - High-Throughput Screening
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- GLP Toxicology
- In Vivo PK / PD Studies
- In Vivo Efficacy Models
- Preclinical In Vivo Studies
- Preclinical In Vitro Studies
- Biomarker Assays
- Flow Cytometry Services
- Translational Research
- Discovery Research
- Specialized & Large-Animal Models
- Oncology Specialty Services
- Immunology & Inflammation Services
- Target Identification & Validation
- Genetic Toxicology
- Immunogenicity Assays (ADA / NAb)
| - Discovery Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- Protein Engineering
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Medical Writing
- Pharmacovigilance & Drug Safety
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
|
|---|
| Modalities | - Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- Cell Therapy
| - Small Molecule
- Peptide
- Oligonucleotide
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- mRNA
- Cell Therapy
- Gene Therapy
- Vaccine
|
|---|
| Indications | - Oncology
- Immunology
- Infectious Disease
| - Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health
|
|---|
| Locations | - Global Headquarters, Malvern, PA, USA
- Hershey, Hershey, PA, USA
- Freiburg, Freiburg, Freiburg, Germany
- Heidelberg, Heidelberg, Heidelberg, Germany
- Research Facility, Hershey, PA, USA
- Research Facility, Freiburg, Freiburg, Germany
- Research Facility, Heidelberg, Heidelberg, Germany
| - Headquarters, Shanghai, Pudong, China
- Global Operations, Asia, Europe, North America
|
|---|
| Certifications | - ISO · Identifier: ISO 9001:2015
| Data not yet provided. |
|---|
| Reviews | Review summary appears after site-level review signal gate opens. | Review summary appears after site-level review signal gate opens. |
|---|